Kevin McFarthing

Shades of grey: The continuum of therapies for Parkinson's disease along the spectrum of credibility - Araceli Alonso-Canovas, Olaf M Dekkers, Bas Bloem,

journals.sagepub.com/doi/10.1177/...

S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for #Parkinsons; Favorable safety & efficacy profile of A9-DPC in 12 participants at 12 months compared to baseline
www.manilatimes.net/2025/07/21/t...

Pharmather eyes commercialization of Parkinson’s ketamine drug The FDA plans to make a decision on Aug. 9 regarding a ketamine-based product that Pharmather hopes to investigate for Parkinson's dyskinesia.

parkinsonsnewstoday.com/news/pharmat...

Interesting - more data on tanganil (acetyl-leucine) - this is a 2-year case study in a patient with #Parkinsons & REM sleep behaviour disorder (RBD); Treatment helps with RBD symptoms; PD analysis is in the supplemental data file
link.springer.com/article/10.1...

Gaining Ground: The Pursuit of Improving and Introducing New Parkinson’s Medications

A nice summary of my recent webinar with the Parkinson's Foundation on the Parkinson's drug development pipeline @ParkinsonDotOrg
www.parkinson.org/blog/awarene...

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s...

The press summary associated with this research: www.globenewswire.com/news-release...

Exploratory digital outcome measures of motor sign progression in #Parkinsons collected by Roche in their Phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab have been published - encouraging data for digital biomarkers
www.nature.com/articles/s41...

Australian Parkinson's Mission Channel 9 News - Prof. Simon Lewis Very grateful to Gaby Rogers and the Channel 9 News team for highlighting the work of the Australian Parkinson’s Mission.

The Mission continues and APM002 is now recruiting:
profsimonlewis.com/australian-p...
Register your interest here:
bit.ly/PDRC_Trials
@scienceofpd.bsky.social @cureparkinsons.org.uk

Expert Briefing: The Latest Advances in Parkinson’s Research and Treatment This webinar will cover the current medication pipeline, highlighting new therapies and their potential impact on symptom management.

I'm delighted to be presenting the next Expert Briefing for the Parkinson's Foundation on the latest advances in Parkinson's research and treatment on April 9th. Everybody is welcome to attend. More details at www.parkinson.org/events/2025/... #Parkinsons

Movers and Shakers: The Gut When I was growing up, my mother had a long list of subjects unsuitable for polite conversation.

rorycellanjones.substack.com/p/movers-and... Talking about your digestive system used to be a no no but nowadays everyone seems to want you know about their gut health. Including the Movers and Shakers - this week’s episode is all about your gut and Parkinson’s. Warning - may include constipation

A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease - npj Parkinson's Disease npj Parkinson's Disease - A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease

A very interesting paper looking at a personalised approach to the "loss of function" and "gain of function" of alpha-synuclein in Parkinson's

www.nature.com/articles/s41...

Celon Pharma CPL 36, a phosphodiesterase 10a inhibitor, met all trial endpoints in phase 2, for the treatment of Parkinson’s dyskinesia

celonpharma.com/en/current-r...

IRLab report 42% reduction in falls in Parkinson's in a phase 2b study of piperimat - but not significant vs placebo.

irlab.se/mfn_news/irl...

New research reports low CSF Aβ42 levels are associated with accelerated cognitive decline in Dementia with Lewy bodies, while reduced CSF GCase activity predicts faster cognitive decline in #Parkinsons
onlinelibrary.wiley.com/doi/full/10....

It's the data, stupid Unlocking innovation in the NHS

open.substack.com/pub/rorycell... At an NHS conference I was asked a hard question - how to solve the problem of innovation. I hadn’t a clue but suspected that data might play a part..,

The research behind adaptive deep brain stimulation for Parkinson’s disease We speak with neurologist Helen Bronte-Stewart, who conducted research that led to the development of a technology recently approved by the U.S. Food and Drug Administration.

A new adaptive deep brain stimulation (aDBS) technology, developed by Helen Bronte-Stewart, has been FDA-approved for Parkinson’s treatment. This personalized approach adjusts electrical pulses based on brain signals, improving patient outcomes! #Parkinsons med.stanford.edu/news/all-new...

"While finding biomarkers is a mandatory step for better precision medicine & optimal patient stratification in therapeutic trials, we argue that a biological definition of #Parkinsons based on a single biomarker will struggle to account for the complexity"
journals.sagepub.com/doi/10.1177/...

Oooohh, hello Cure Parkinson's - welcome to Bluesky!
bsky.app/profile/cure...

Further epidemiological support for GLP-1 receptor agonists: "After 10 years, sustained GLP-1RA users had a lower hazard ratio (HR 0.57 (95% CI 0.37;0.85)) & absolute risk difference (−0.24 (95% CI −0.63 to 0.15))" of #Parkinsons compared to DPP-4i users
onlinelibrary.wiley.com/doi/10.1111/...

Supernus' 4th try proves the charm with long-awaited FDA approval for Parkinson's infusion pump Onapgo Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is meant to allow patients more control over their "off" time, or the instances w...

Supernus finally gets approval for apomorphine pump in Parkinson’s

www.fiercepharma.com/pharma/four-...

Monthly Research Review – January 2025 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2025. Th…

Simon’s terrific monthly Research review for January - scienceofparkinsons.com/2025/01/31/j...

Inhibikase Halts Parkinson's Drug Development to Focus on PAH By Investing.com Inhibikase Halts Parkinson's Drug Development to Focus on PAH

Inhibikase halts Parkinson’s drug development after failure of Risvodetinib in phase 2

www.investing.com/news/sec-fil...

Outstanding article from Simon @scienceofpd , looking forward to the next two chapters

JPM25: Medtronic begins rolling out adaptive brain stimulation for Parkinson's after EU approval SAN FRANCISCO—While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes | SAN FRANCI...

Adaptive DBS for Parkinson's approved in Europe

www.fiercebiotech.com/medtech/jpm2...

Adaptive DBS - a 24/7 surgeon in your head In the six decades or so since Levodopa came on the scene there has really been only one other innovation that has proved to be a major breakthrough in the treatment of Parkinson’s.

open.substack.com/pub/rorycell... New improved DBS is like having your neurologist available 24/7 - latest from my healthtech Substack. #Parkinsons

JPM25: Bayer moves allogeneic cell therapy into phase 3 Parkinson's trial Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell therapy i | ...

Bayer moves cell replacement therapy for Parkinson’s straight to phase 3

www.fiercebiotech.com/biotech/jpm2...

Do you know the tips when looking for work with a chronic disease like Parkinson? “If given a chance, and also if embraced by the workplace culture, these folks can in many cases even outperform their colleagues.”
www.healthcentral.com/chronic-heal... #Parkinsons

Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpointsPrasinezumab continues to be well tolerated and no new safety signals were.....

www.roche.com/media/releas...

Thanks Iain

UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2 UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. | UCB’s Novartis-partnered investigational small molecule has failed ...

www.fiercebiotech.com/biotech/ucbs...